0000310764-26-000031
SEC filingQ1 delivered solid revenue growth and strong operating leverage, driving double-digit bottom-line expansion despite higher interest costs from 2025 debt issuances, with robust cash generation from favorable working capital changes.
Stryker Corporation reported Q1 FY2026 results reflecting resilient performance across its two reportable segments: MedSurg and Neurotechnology, and Orthopaedics. Revenue grew 2.6% to $6.0 billion from $5.9 billion in the prior year quarter, propelled by higher product shipments and unit volume increases across most MedSurg and Neurotechnology businesses, all Orthopaedics businesses, as well as Instruments and Vascular. This volume-driven top-line expansion underscores Stryker's positioning to achieve sales growth at the high end of the MedTech industry.
Gross profit increased 1.8% to $3.8 billion, representing a 63.3% gross margin on the expanded revenue base. Operating income advanced more sharply by 11.8% to $936 million, achieving a 15.5% operating margin. This outperformance relative to revenue growth demonstrates operating leverage through disciplined expense control, enabling bottom-line expansion even amid a challenging macroeconomic environment marked by inflation, market volatility, and geopolitical risks including potential tariffs.
Net income rose 13.9% to $745 million, with diluted EPS up 14.2% to $1.93 per share. The stronger earnings were tempered by higher interest expense, primarily attributable to 2025 debt issuances, and a decrease in other income due to lower interest income in 2026. These non-operating dynamics highlight the cost of financing growth initiatives while maintaining a strong balance sheet.
Looking forward, Stryker's reorganized structure maintains these two core segments, each driving the company's MedTech leadership. While broader economic uncertainties pose risks to operations, the quarter's results affirm operational momentum from higher shipments and effective working capital management.